Mr. Paul Pathak reports
WAYLAND SELECTED AS ONE OF THREE GROUPS, PENDING REVIEW PERIOD, FOR CANNABIS PRODUCTION LICENSES IN GERMANY
Wayland Group Corp. has been selected by the German Federal Institute for Drugs and Medical Devices (BfArM), through its German joint venture Demecan GmbH, to begin domestic production of medical cannabis for the rapidly growing German patient population. The company is one of three groups that have been selected and is subject to a review period, after which a final decision will be made no earlier than April 17, 2019.
From the beginning, the market opportunity for medical cannabis in Germany has been a key part of Wayland's global growth strategy. The company has always prioritized Germany as one of the most exciting medical cannabis markets in the world given its progressive regulations, rapidly expanding patient population and insurance coverage for over 60 per cent of prescriptions.
"This is a watershed moment for our operations in Germany as it validates the early entry by our company into that market. I congratulate Ben and his team on the ground in Germany and our partner Demecan, and thank them for their hard work. We hope and expect to see similar successes in other international markets, where Wayland has made similar early entries," stated Wayland chairman Paul Pathak.
About Wayland Group
Wayland is a vertically integrated cultivator and processor of cannabis. The company was founded in 2013 and is based in Burlington, Ont., Canada, and Munich, Germany, with production facilities in Langton, Ont., where it operates a cannabis cultivation, extraction, formulation and distribution business under federal licences from the government of Canada. The company also has production operations in Dresden, Saxony, Germany, Regensdorf, Switzerland, and Allesandria, Piedmont, Italy. Wayland will continue to pursue new opportunities globally, including the consummation of its previously announced transactions in the United Kingdom, Australia, Colombia, and Argentina, in its effort to enhance lives through cannabis.
We seek Safe Harbor.
© 2019 Canjex Publishing Ltd. All rights reserved.